{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:03:09Z","timestamp":1775581389765,"version":"3.50.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31DA054849"],"award-info":[{"award-number":["F31DA054849"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA053136"],"award-info":[{"award-number":["R01DA053136"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI102623"],"award-info":[{"award-number":["T32AI102623"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute on Drug Abuse,United States","award":["U01DA036297"],"award-info":[{"award-number":["U01DA036297"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AI094189"],"award-info":[{"award-number":["1P30AI094189"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Substance use disorder treatment and recovery support services are critical for achieving and maintaining recovery. There are limited data on how structural and social changes due to the COVID-19 pandemic impacted individual-level experiences with substance use disorder treatment-related services among community-based samples of people who inject drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>People with a recent history of injection drug use who were enrolled in the community-based AIDS Linked to the IntraVenous Experience study in Baltimore, Maryland participated in a one-time, semi-structured interview between July 2021 and February 2022 about their experiences living through the COVID-19 pandemic (n\u2009=\u200928). An iterative inductive coding process was used to identify themes describing how structural and social changes due to the COVID-19 pandemic affected participants\u2019 experiences with substance use disorder treatment-related services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of participants was 54\u00a0years (range\u2009=\u200924\u201373); 10 (36%) participants were female, 16 (57%) were non-Hispanic Black, and 8 (29%) were living with HIV. We identified several structural and social changes due the pandemic that acted as barriers and facilitators to individual-level engagement in treatment with medications for opioid use disorder (MOUD) and recovery support services (e.g., support group meetings). New take-home methadone flexibility policies temporarily facilitated engagement in MOUD treatment, but other pre-existing rigid policies and practices (e.g., zero-tolerance) were counteracting barriers. Changes in the illicit drug market were both a facilitator and barrier to MOUD treatment. Decreased availability and pandemic-related adaptations to in-person services were a barrier to recovery support services. While telehealth expansion facilitated engagement in recovery support group meetings for some participants, other participants faced digital and technological barriers. These changes in service provision also led to diminished perceived quality of both virtual and in-person recovery support group meetings. However, a facilitator of recovery support was increased accessibility of individual service providers (e.g., counselors and Sponsors).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Structural and social changes across several socioecological\u00a0levels created new barriers and facilitators of individual-level engagement in substance use disorder treatment-related services. Multilevel interventions are needed to improve access to and engagement in high-quality substance use disorder treatment and recovery support services among people who inject drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01008-8","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:02:19Z","timestamp":1715144539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland"],"prefix":"10.1186","volume":"21","author":[{"given":"Eshan U.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail K.","family":"Winiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Ching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine G.","family":"Schluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky L.","family":"Genberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"234","key":"1008_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109428","volume":"1","author":"EW Hall","year":"2022","unstructured":"Hall EW, Rosenberg ES, Jones CM, Asher A, Valverde E, Bradley H. Estimated number of injection-involved drug overdose deaths, United States, 2000\u20132018. Drug Alcohol Depend. 2022;1(234): 109428.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jama.2021.8012","volume":"326","author":"JS Faust","year":"2021","unstructured":"Faust JS, Du C, Mayes KD, Li SX, Lin Z, Barnett ML, et al. Mortality from drug overdoses, homicides, unintentional injuries, motor vehicle crashes, and suicides during the pandemic, March\u2013August 2020. JAMA. 2021;326(1):84\u20136.","journal-title":"JAMA"},{"issue":"1","key":"1008_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","volume":"76","author":"H Bradley","year":"2023","unstructured":"Bradley H, Hall EW, Asher A, Furukawa NW, Jones CM, Shealey J, et al. Estimated number of people who inject drugs in the United States. Clin Infect Dis. 2023;76(1):96\u2013102.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1008_CR4","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/cid\/ciaa008","volume":"71","author":"NL McCarthy","year":"2020","unstructured":"McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial infections associated with substance use disorders, large cohort of United States hospitals, 2012\u20132017. Clin Infect Dis. 2020;71(7):e37-44.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1008_CR5","doi-asserted-by":"publisher","first-page":"ofw157","DOI":"10.1093\/ofid\/ofw157","volume":"3","author":"AG Wurcel","year":"2016","unstructured":"Wurcel AG, Anderson JE, Chui KKH, Skinner S, Knox TA, Snydman DR, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3):ofw157.","journal-title":"Open Forum Infect Dis"},{"issue":"13","key":"1008_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMp1716871","volume":"378","author":"TJ Liang","year":"2018","unstructured":"Liang TJ, Ward JW. Hepatitis C in injection-drug users - a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169\u201371.","journal-title":"N Engl J Med"},{"issue":"14","key":"1008_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","volume":"69","author":"AB Ryerson","year":"2020","unstructured":"Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases - United States, 2009\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(14):399\u2013404.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1008_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2105\/AJPH.2019.305366","volume":"110","author":"C Alpren","year":"2020","unstructured":"Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, et al. Opioid use fueling HIV transmission in an Urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015\u20132018. Am J Public Health. 2020;110(1):37\u201344.","journal-title":"Am J Public Health"},{"issue":"5 Suppl 1","key":"1008_CR9","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/j.amepre.2021.04.037","volume":"61","author":"SE Buskin","year":"2021","unstructured":"Buskin SE, Erly SJ, Glick SN, Lechtenberg RJ, Kerani RP, Herbeck JT, et al. Detection and response to an HIV cluster: people living homeless and using drugs in seattle, Washington. Am J Prev Med. 2021;61(5 Suppl 1):S160\u20139.","journal-title":"Am J Prev Med"},{"issue":"16","key":"1008_CR10","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone \u2014 Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"1008_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.15585\/mmwr.mm6810a6","volume":"68","author":"K Cranston","year":"2019","unstructured":"Cranston K, Alpren C, John B, Dawson E, Roosevelt K, Burrage A, et al. Notes from the field: HIV diagnoses among persons who inject drugs - Northeastern Massachusetts, 2015\u20132018. MMWR Morb Mortal Wkly Rep. 2019;68(10):253\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"103889","DOI":"10.1016\/j.drugpo.2022.103889","volume":"110","author":"H Bradley","year":"2022","unstructured":"Bradley H, Austin C, Allen ST, Asher A, Bartholomew TS, Board A, et al. A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic. Int J Drug Policy. 2022;110:103889.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1008_CR13","doi-asserted-by":"publisher","first-page":"e0260286","DOI":"10.1371\/journal.pone.0260286","volume":"16","author":"SA Strathdee","year":"2021","unstructured":"Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, et al. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. PLoS ONE. 2021;16(11):e0260286.","journal-title":"PLoS ONE"},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2022.03.048","volume":"56","author":"G Ao","year":"2022","unstructured":"Ao G, Li A, Wang Y, Li J, Tran C, Chen M, et al. Opioid usage and COVID-19 prognosis: a systematic review and meta-analysis. Am J Emerg Med. 2022;56:51\u20136.","journal-title":"Am J Emerg Med"},{"issue":"234","key":"1008_CR15","doi-asserted-by":"publisher","first-page":"109383","DOI":"10.1016\/j.drugalcdep.2022.109383","volume":"1","author":"DS Hasin","year":"2022","unstructured":"Hasin DS, Fink DS, Olfson M, Saxon AJ, Malte C, Keyes KM, et al. Substance use disorders and COVID-19: an analysis of nation-wide veterans health administration electronic health records. Drug Alcohol Depend. 2022;1(234):109383.","journal-title":"Drug Alcohol Depend"},{"key":"1008_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/add.16105","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Basaraba C, Corbeil T, Allen B, Schultebraucks K, et al. COVID-19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems. Addiction. 2023. https:\/\/doi.org\/10.1111\/add.16105.","journal-title":"Addiction"},{"issue":"1","key":"1008_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","volume":"26","author":"QQ Wang","year":"2021","unstructured":"Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30\u20139.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1008_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","volume":"13","author":"T Rhodes","year":"2002","unstructured":"Rhodes T. The \u2018risk environment\u2019: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85\u201394.","journal-title":"Int J Drug Policy"},{"issue":"345","key":"1008_CR19","doi-asserted-by":"publisher","first-page":"e5945","DOI":"10.1136\/bmj.e5945","volume":"3","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;3(345):e5945.","journal-title":"BMJ"},{"issue":"9","key":"1008_CR20","first-page":"CD012021","volume":"9","author":"L Platt","year":"2017","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):CD012021.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1008_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/add.15316","volume":"116","author":"CF Ferraro","year":"2021","unstructured":"Ferraro CF, Stewart DE, Grebely J, Tran LT, Zhou S, Puca C, et al. Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. Addiction. 2021;116(7):1664\u201376.","journal-title":"Addiction"},{"issue":"1","key":"1008_CR22","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","volume":"73","author":"J Grebely","year":"2021","unstructured":"Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(1):e107\u201318.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1008_CR23","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/cid\/ciab578","volume":"73","author":"J Kim","year":"2021","unstructured":"Kim J, Lesko CR, Fojo AT, Keruly JC, Moore RD, Chander G, et al. The effect of buprenorphine on human immunodeficiency virus viral suppression. Clin Infect Dis. 2021;73(11):1951\u20136.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1008_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094\u2013104.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1008_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo","year":"2021","unstructured":"Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiat"},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.","journal-title":"Int J Drug Policy"},{"key":"1008_CR27","unstructured":"Center for Substance Abuse Treatment. What Are Peer Recovery Support Services? HHS Publication No. (SMA) 09\u2013-4454 [Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services; 2009 [cited 2023 Feb 10]. Available from: https:\/\/store.samhsa.gov\/product\/What-Are-Peer-Recovery-Support-Services-\/SMA09-4454?referer=from_search_result"},{"issue":"1","key":"1008_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0376-8716(96)01292-6","volume":"43","author":"RD Weiss","year":"1996","unstructured":"Weiss RD, Griffin ML, Najavits LM, Hufford C, Kogan J, Thompson HJ, et al. Self-help activities in cocaine dependent patients entering treatment: results from the NIDA collaborative cocaine treatment study. Drug Alcohol Depend. 1996;43(1):79\u201386.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/08897077.2012.691452","volume":"34","author":"SE Zemore","year":"2013","unstructured":"Zemore SE, Subbaraman M, Tonigan JS. Involvement in 12-Step activities and treatment outcomes. Subst Abuse. 2013;34(1):60\u20139.","journal-title":"Subst Abuse"},{"issue":"2","key":"1008_CR30","doi-asserted-by":"publisher","first-page":"13469","DOI":"10.4088\/JCP.18m12292","volume":"80","author":"RD Weiss","year":"2019","unstructured":"Weiss RD, Griffin ML, Marcovitz DE, Hilton BT, Fitzmaurice GM, McHugh RK, et al. Correlates of opioid abstinence in a 42-month posttreatment naturalistic follow-up study of prescription opioid dependence. J Clin Psychiatry. 2019;80(2):13469.","journal-title":"J Clin Psychiatry"},{"key":"1008_CR31","doi-asserted-by":"publisher","first-page":"209238","DOI":"10.1016\/j.josat.2023.209238","volume":"158","author":"L Kane","year":"2024","unstructured":"Kane L, Benson K, Stewart ZJ, Daughters SB. The impact of spiritual well-being and social support on substance use treatment outcomes within a sample of predominantly Black\/African American adults. J Subst Use Addictn Treat. 2024;158:209238.","journal-title":"J Subst Use Addictn Treat"},{"key":"1008_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.01.003","volume":"63","author":"EL Bassuk","year":"2016","unstructured":"Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abuse Treat. 2016;63:1\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"1008_CR33","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3389\/fpsyg.2019.01052","volume":"13","author":"D Eddie","year":"2019","unstructured":"Eddie D, Hoffman L, Vilsaint C, Abry A, Bergman B, Hoeppner B, et al. Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching. Front Psychol. 2019;13(10):1052.","journal-title":"Front Psychol"},{"issue":"229","key":"1008_CR34","doi-asserted-by":"publisher","first-page":"109123","DOI":"10.1016\/j.drugalcdep.2021.109123","volume":"1","author":"MA Gormley","year":"2021","unstructured":"Gormley MA, Pericot-Valverde I, Diaz L, Coleman A, Lancaster J, Ortiz E, et al. Effectiveness of peer recovery support services on stages of the opioid use disorder treatment cascade: a systematic review. Drug Alcohol Depend. 2021;1(229):109123.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"1008_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/SAR.S81535","volume":"29","author":"K Tracy","year":"2016","unstructured":"Tracy K, Wallace SP. Benefits of peer support groups in the treatment of addiction. Subst Abuse Rehabil. 2016;29(7):143\u201354.","journal-title":"Subst Abuse Rehabil"},{"issue":"Suppl 3","key":"1008_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(Suppl 3):954\u201363.","journal-title":"J Gen Intern Med"},{"issue":"14","key":"1008_CR37","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"key":"1008_CR38","doi-asserted-by":"crossref","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020;2020.","DOI":"10.31478\/202004b"},{"issue":"127","key":"1008_CR39","doi-asserted-by":"publisher","first-page":"108347","DOI":"10.1016\/j.jsat.2021.108347","volume":"1","author":"R Abadie","year":"2021","unstructured":"Abadie R, McLean K, Habecker P, Dombrowski K. Treatment trajectories and barriers in opioid agonist therapy for people who inject drugs in rural Puerto Rico. J Subst Abuse Treat. 2021;1(127):108347.","journal-title":"J Subst Abuse Treat"},{"issue":"224","key":"1008_CR40","doi-asserted-by":"publisher","first-page":"108717","DOI":"10.1016\/j.drugalcdep.2021.108717","volume":"1","author":"MF McLaughlin","year":"2021","unstructured":"McLaughlin MF, Li R, Carrero ND, Bain PA, Chatterjee A. Opioid use disorder treatment for people experiencing homelessness: a scoping review. Drug Alcohol Depend. 2021;1(224):108717.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12954-023-00795-w","volume":"20","author":"AK Winiker","year":"2023","unstructured":"Winiker AK, Schneider KE, Hamilton White R, O\u2019Rourke A, Grieb SM, Allen ST. A qualitative exploration of barriers and facilitators to drug treatment services among people who inject drugs in West Virginia. Harm Reduct J. 2023;20(1):69.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1008_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","volume":"41","author":"HS Reisinger","year":"2009","unstructured":"Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O\u2019Grady KE, et al. Premature discharge from methadone treatment: patient perspectives. J Psychoact Drugs. 2009;41(3):285\u201396.","journal-title":"J Psychoact Drugs"},{"issue":"46","key":"1008_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addbeh.2015.01.038","volume":"1","author":"JD Koehn","year":"2015","unstructured":"Koehn JD, Bach P, Hayashi K, Nguyen P, Kerr T, Milloy MJ, et al. Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users. Addict Behav. 2015;1(46):1\u20134.","journal-title":"Addict Behav"},{"issue":"4","key":"1008_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1081\/ADA-200068114","volume":"31","author":"JJ Lloyd","year":"2005","unstructured":"Lloyd JJ, Ricketts EP, Strathdee SA, Cornelius LJ, Bishai D, Huettner S, et al. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31(4):555\u201370.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"1008_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1037\/adb0000934","volume":"38","author":"EM Schweitzer","year":"2024","unstructured":"Schweitzer EM, Urmanche A, Kong J, Hafezi S, Zhao J, Cooperman NA, et al. The role of social connection in opioid use disorder treatment engagement. Psychol Addict Behav. 2024;38(2):222\u201330.","journal-title":"Psychol Addict Behav"},{"issue":"1","key":"1008_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11469-012-9402-5","volume":"11","author":"V Earnshaw","year":"2013","unstructured":"Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addiction. 2013;11(1):110\u201322.","journal-title":"Int J Ment Health Addiction"},{"issue":"57","key":"1008_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","volume":"1","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;1(57):104\u201310.","journal-title":"Int J Drug Policy"},{"key":"1008_CR48","doi-asserted-by":"publisher","first-page":"108651","DOI":"10.1016\/j.drugalcdep.2021.108651","volume":"221","author":"NY Hall","year":"2021","unstructured":"Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: a systematic review from the client perspective. Drug Alcohol Depend. 2021;221:108651.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1008_CR50","first-page":"qxad013","volume":"1","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BCE. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States. Health Aff Sch. 2023;1(1):qxad013.","journal-title":"Health Aff Sch"},{"issue":"3","key":"1008_CR51","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","volume":"8","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Levin E, Dooling BCE. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. Lancet Public Health. 2023;8(3):e238\u201346.","journal-title":"Lancet Public Health"},{"issue":"11","key":"1008_CR52","doi-asserted-by":"publisher","first-page":"e213833","DOI":"10.1001\/jamahealthforum.2021.3833","volume":"2","author":"SC Pessar","year":"2021","unstructured":"Pessar SC, Boustead A, Ge Y, Smart R, Pacula RL. Assessment of state and federal health policies for opioid use disorder treatment during the COVID-19 pandemic and beyond. JAMA Health Forum. 2021;2(11):e213833.","journal-title":"JAMA Health Forum"},{"issue":"1","key":"1008_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13011-021-00395-6","volume":"16","author":"K Alexander","year":"2021","unstructured":"Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021;16(1):60.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1008_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","volume":"43","author":"B Chan","year":"2022","unstructured":"Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R. Opioid treatment programs, telemedicine and COVID-19: A scoping review. Substance Abuse. 2022;43(1):539\u201346.","journal-title":"Substance Abuse"},{"issue":"22","key":"1008_CR55","doi-asserted-by":"publisher","first-page":"12094","DOI":"10.3390\/ijerph182212094","volume":"18","author":"D de Vargas","year":"2021","unstructured":"de Vargas D, Pereira CF, Volpato RJ, Lima AVC, da Silva FR, de Oliveira SR, et al. Strategies adopted by addiction facilities during the coronavirus pandemic to support treatment for individuals in recovery or struggling with a substance use disorder: a scoping review. Int J Environ Res Public Health. 2021;18(22):12094.","journal-title":"Int J Environ Res Public Health"},{"key":"1008_CR56","doi-asserted-by":"publisher","first-page":"109711","DOI":"10.1016\/j.drugalcdep.2022.109711","volume":"242","author":"C Lin","year":"2023","unstructured":"Lin C, Pham H, Zhu Y, Clingan SE, Lin L, Murphy SM, et al. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2023;242:109711.","journal-title":"Drug Alcohol Depend"},{"key":"1008_CR57","doi-asserted-by":"crossref","unstructured":"Parker DG, Zentner D, Burack JA, Wendt DC. The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review. Drugs: Education, Prevention and Policy. 2023;0(0):1\u201314.","DOI":"10.1080\/09687637.2023.2181147"},{"issue":"1","key":"1008_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S2215-0366(22)00374-1","volume":"10","author":"JTW Teck","year":"2023","unstructured":"Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, Potenza MN, et al. Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. Lancet Psychiatry. 2023;10(1):50\u201364.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"1008_CR59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17538068.2022.2138243","volume":"16","author":"G Capurro","year":"2023","unstructured":"Capurro G, Maier R, Tustin J, Jardine CG, Driedger SM. \u2018Stay home and stay safe \u2026 but maybe you can have somebody over\u2019: public perceptions of official COVID-19 messages during the 2020 holiday season in Canada. J Commun Healthc. 2023;16(3):279\u201386.","journal-title":"J Commun Healthc"},{"issue":"2","key":"1008_CR60","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/ajt.16645","volume":"22","author":"G French","year":"2022","unstructured":"French G, Hulse M, Nguyen D, Sobotka K, Webster K, Corman J, et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic\u2014United States, July 2020\u2013july 2021. Am J Transpl. 2022;22(2):654\u20137.","journal-title":"Am J Transpl"},{"issue":"4","key":"1008_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.annemergmed.2022.05.036","volume":"80","author":"KLH Ioannides","year":"2022","unstructured":"Ioannides KLH, Dekker AM, Shin ME, Schriger DL. Ambulances required to relieve overcapacity hospitals: a novel measure of hospital strain during the COVID-19 pandemic in the United States. Ann Emerg Med. 2022;80(4):301-313.e3.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"1008_CR62","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1097\/ADM.0000000000000853","volume":"16","author":"E Gleason","year":"2022","unstructured":"Gleason E, Nolan NS, Marks LR, Habrock T, Liang SY, Durkin MJ. Barriers to care experienced by patients who inject drugs during the COVID-19 pandemic: a qualitative analysis. J Addict Med. 2022;16(2):e133\u20136.","journal-title":"J Addict Med"},{"issue":"3","key":"1008_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/JHQ.0000000000000380","volume":"45","author":"KA Muellers","year":"2023","unstructured":"Muellers KA, Andreadis K, Ancker JS, Horowitz CR, Kaushal R, Lin JJ. Provider and patient experiences of delays in primary care during the early COVID-19 pandemic. J Healthc Qual. 2023;45(3):169\u201376.","journal-title":"J Healthc Qual"},{"key":"1008_CR64","doi-asserted-by":"publisher","first-page":"103435","DOI":"10.1016\/j.trd.2022.103435","volume":"110","author":"A Kar","year":"2022","unstructured":"Kar A, Carrel AL, Miller HJ, Le HTK. Public transit cuts during COVID-19 compound social vulnerability in 22 US cities. Transp Res D Transp Environ. 2022;110:103435.","journal-title":"Transp Res D Transp Environ"},{"key":"1008_CR65","doi-asserted-by":"publisher","first-page":"102271","DOI":"10.1016\/j.tre.2021.102271","volume":"148","author":"P Chowdhury","year":"2021","unstructured":"Chowdhury P, Paul SK, Kaisar S, Moktadir MDA. COVID-19 pandemic related supply chain studies: a systematic review. Transp Res Part E Logist Transp Rev. 2021;148:102271.","journal-title":"Transp Res Part E Logist Transp Rev"},{"key":"1008_CR66","doi-asserted-by":"publisher","first-page":"108584","DOI":"10.1016\/j.drugalcdep.2021.108584","volume":"221","author":"BL Genberg","year":"2021","unstructured":"Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: a rapid phone survey in Baltimore, Maryland. Drug Alcohol Depend. 2021;221:108584.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1008_CR67","first-page":"464","volume":"122","author":"EJ Bailey","year":"2023","unstructured":"Bailey EJ, Westergaard RP, Kaya C, Becker M, Mijal K, Seal D, et al. Effects of COVID-19 on overdose risk behaviors among people who inject drugs in wisconsin. WMJ. 2023;122(5):464\u20138.","journal-title":"WMJ"},{"issue":"1","key":"1008_CR68","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12954-021-00568-3","volume":"18","author":"Y Aponte-Melendez","year":"2021","unstructured":"Aponte-Melendez Y, Mateu-Gelabert P, Fong C, Eckhardt B, Kapadia S, Marks K. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm Reduct J. 2021;18(1):118.","journal-title":"Harm Reduct J"},{"issue":"244","key":"1008_CR69","doi-asserted-by":"publisher","first-page":"109802","DOI":"10.1016\/j.drugalcdep.2023.109802","volume":"1","author":"EU Patel","year":"2023","unstructured":"Patel EU, Astemborski J, Feder KA, Rudolph JE, Winiker A, Sosnowski DW, et al. Temporal association of pre-pandemic perceived social support with psychological resilience and mental well-being during the COVID-19 pandemic among people with a history of injection drug use. Drug Alcohol Depend. 2023;1(244):109802.","journal-title":"Drug Alcohol Depend"},{"key":"1008_CR70","doi-asserted-by":"publisher","first-page":"103391","DOI":"10.1016\/j.drugpo.2021.103391","volume":"98","author":"JM Kesten","year":"2021","unstructured":"Kesten JM, Holland A, Linton MJ, Family H, Scott J, Horwood J, et al. Living under coronavirus and injecting drugs in bristol (LUCID-B): a qualitative study of experiences of COVID-19 among people who inject drugs. Int J Drug Policy. 2021;98:103391.","journal-title":"Int J Drug Policy"},{"key":"1008_CR71","doi-asserted-by":"publisher","first-page":"104060","DOI":"10.1016\/j.drugpo.2023.104060","volume":"117","author":"JJ Carroll","year":"2023","unstructured":"Carroll JJ, Rossi SL, Vetrova MV, Blokhina E, Sereda Y, Lioznov D, et al. The impacts of COVID-19 on structural inequities faced by people living with HIV who inject drugs: a qualitative study in St. Petersburg, Russia. Int J Drug Policy. 2023;117:104060.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1008_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12954-022-00601-z","volume":"19","author":"D Otiashvili","year":"2022","unstructured":"Otiashvili D, Mgebrishvili T, Beselia A, Vardanashvili I, Dumchev K, Kiriazova T, et al. The impact of the COVID-19 pandemic on illicit drug supply, drug-related behaviour of people who use drugs and provision of drug related services in Georgia: results of a mixed methods prospective cohort study. Harm Reduct J. 2022;19(1):25.","journal-title":"Harm Reduct J"},{"issue":"15","key":"1008_CR73","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.3390\/ijerph19159751","volume":"19","author":"EL Kelly","year":"2022","unstructured":"Kelly EL, Reed MK, Schoenauer KM, Smith K, Scalia-Jackson K, Kay Hill S, et al. A qualitative exploration of the functional, social, and emotional impacts of the COVID-19 pandemic on people who use drugs. Int J Environ Res Public Health. 2022;19(15):9751.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1008_CR74","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s10461-022-03851-x","volume":"27","author":"L Wiessing","year":"2023","unstructured":"Wiessing L, Sypsa V, Abagiu AO, Arble A, Berndt N, Bosch A, et al. Impact of COVID-19 & response measures on HIV-HCV prevention services and social determinants in people who inject drugs in 13 sites with recent HIV outbreaks in Europe. N Am Israel AIDS Behav. 2023;27(4):1140\u201353.","journal-title":"N Am Israel AIDS Behav"},{"key":"1008_CR75","doi-asserted-by":"publisher","first-page":"110954","DOI":"10.1016\/j.drugalcdep.2023.110954","volume":"251","author":"KA Feder","year":"2023","unstructured":"Feder KA, Patel EU, Buresh M, Kirk GD, Mehta SH, Genberg BL. Trends in self-reported non-fatal overdose and patterns of substance use before and during the COVID-19 pandemic in a prospective cohort of adults who have injected drugs \u2013 Baltimore, Maryland, 2014\u20132022. Drug Alcohol Depend. 2023;251:110954.","journal-title":"Drug Alcohol Depend"},{"issue":"111","key":"1008_CR76","first-page":"103923","volume":"22","author":"KE Schneider","year":"2022","unstructured":"Schneider KE, Allen ST, Rouhani S, Morris M, Haney K, Saloner B, et al. Increased solitary drug use during COVID-19: an unintended consequence of social distancing. Int J Drug Policy. 2022;22(111):103923.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1008_CR77","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1037\/0003-066X.32.7.513","volume":"32","author":"U Bronfenbrenner","year":"1977","unstructured":"Bronfenbrenner U. Toward an experimental ecology of human development. Am Psychol. 1977;32(7):513.","journal-title":"Am Psychol"},{"key":"1008_CR78","doi-asserted-by":"publisher","first-page":"108923","DOI":"10.1016\/j.jsat.2022.108923","volume":"144","author":"MM Ali","year":"2023","unstructured":"Ali MM, Creedon TB, Jacobus-Kantor L, Sherry TB. National trends in buprenorphine prescribing before and during the COVID-19 pandemic. J Subst Abuse Treat. 2023;144:108923.","journal-title":"J Subst Abuse Treat"},{"key":"1008_CR79","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.drugpo.2022.103680","volume":"104","author":"Z Bouck","year":"2022","unstructured":"Bouck Z, Scheim AI, Gomes T, Ling V, Caudarella A, Werb D. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104:103680.","journal-title":"Int J Drug Policy"},{"key":"1008_CR80","doi-asserted-by":"publisher","first-page":"103870","DOI":"10.1016\/j.drugpo.2022.103870","volume":"110","author":"HT Giang","year":"2022","unstructured":"Giang HT, Duc NQ, Mol\u00e8s JP, Vinh VH, Nagot N, Thanh NTT, et al. Maintaining HIV and HCV prevention and care for people who inject drugs despite COVID-19 in Hai Phong. Vietnam Int J Drug Policy. 2022;110:103870.","journal-title":"Vietnam Int J Drug Policy"},{"issue":"232","key":"1008_CR81","doi-asserted-by":"publisher","first-page":"109263","DOI":"10.1016\/j.drugalcdep.2021.109263","volume":"1","author":"KMA Trayner","year":"2022","unstructured":"Trayner KMA, McAuley A, Palmateer NE, Yeung A, Goldberg DJ, Glancy M, et al. Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study. Drug Alcohol Depend. 2022;1(232):109263.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-022-00660-2","volume":"19","author":"K Thakarar","year":"2022","unstructured":"Thakarar K, Kohut M, Hutchinson R, Bell R, Loeb HE, Burris D, et al. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in a rural American state. Harm Reduct J. 2022;19(1):1\u201313.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1008_CR83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12954-023-00793-y","volume":"20","author":"L Cooper","year":"2023","unstructured":"Cooper L, Rosen JG, Zhang L, Pelaez D, Olatunde PF, Owczarzak J, et al. Exploring the impact of the COVID-19 pandemic on healthcare and substance use service access among women who inject drugs: a qualitative study. Harm Reduct J. 2023;20(1):71.","journal-title":"Harm Reduct J"},{"issue":"7","key":"1008_CR84","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/aje\/kwq441","volume":"173","author":"BL Genberg","year":"2011","unstructured":"Genberg BL, Gange SJ, Go VF, Celentano DD, Kirk GD, Mehta SH. Trajectories of injection drug use over 20 years (1988\u20132008) in Baltimore, Maryland. Am J Epidemiol. 2011;173(7):829\u201336.","journal-title":"Am J Epidemiol"},{"issue":"118","key":"1008_CR85","doi-asserted-by":"publisher","first-page":"104120","DOI":"10.1016\/j.drugpo.2023.104120","volume":"1","author":"JE Rudolph","year":"2023","unstructured":"Rudolph JE, Cepeda JA, Astemborski J, Kirk GD, Mehta SH, Genberg BL. Trajectories of drug treatment and illicit opioid use in the AIDS linked to the IntraVenous experience cohort, 2014\u20132019. Int J Drug Policy. 2023;1(118):104120.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1008_CR86","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/002204269102100406","volume":"21","author":"D Vlahov","year":"1991","unstructured":"Vlahov D, Anthony JC, Mu\u00f1oz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods. J Drug Issues. 1991;21(4):759\u201376.","journal-title":"J Drug Issues"},{"issue":"142","key":"1008_CR87","doi-asserted-by":"publisher","first-page":"108806","DOI":"10.1016\/j.jsat.2022.108806","volume":"1","author":"O Heidari","year":"2022","unstructured":"Heidari O, Genberg BL, Perrin N, Dangerfield DT, Farley JE, Kirk G, et al. Multimorbidity classes indicate differential patterns of health care engagement among people who inject drugs. J Subst Abuse Treat. 2022;1(142):108806.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"1008_CR88","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907.","journal-title":"Qual Quant"},{"key":"1008_CR89","unstructured":"ATLAS.ti 22 Windows [Internet]. 2022. ATLAS.ti scientific software development GmbH. Available from: http:\/\/atlasti.com"},{"issue":"4","key":"1008_CR90","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1020909529486","volume":"36","author":"H Boeije","year":"2002","unstructured":"Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391\u2013409.","journal-title":"Qual Quant"},{"key":"1008_CR91","volume-title":"The discovery of grounded theory: strategies for qualitative research","author":"BG Glaser","year":"1967","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Chicago, IL: Aldine Transactions; 1967."},{"key":"1008_CR92","doi-asserted-by":"publisher","first-page":"208946","DOI":"10.1016\/j.josat.2022.208946","volume":"145","author":"TM Abidogun","year":"2023","unstructured":"Abidogun TM, Cole TO, Massey E, Kleinman M, Greenblatt AD, Seitz-Brown CJ, et al. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore. J Subst Use Addict Treat. 2023;145:208946.","journal-title":"J Subst Use Addict Treat"},{"issue":"135","key":"1008_CR93","doi-asserted-by":"publisher","first-page":"108655","DOI":"10.1016\/j.jsat.2021.108655","volume":"1","author":"MTH Harris","year":"2022","unstructured":"Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. \u201cNo home to take methadone to\u201d: experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Subst Abuse Treat. 2022;1(135):108655.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1008_CR94","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","volume":"16","author":"XA Levander","year":"2021","unstructured":"Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):72.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1008_CR95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13011-022-00449-3","volume":"17","author":"DP Watson","year":"2022","unstructured":"Watson DP, Staton MD, Grella CE, Scott CK, Dennis ML. Navigating intersecting public health crises: a qualitative study of people with opioid use disorders\u2019 experiences during the COVID-19 pandemic. Subst Abuse Treat Prev Policy. 2022;17(1):22.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1008_CR96","doi-asserted-by":"publisher","first-page":"104058","DOI":"10.1016\/j.drugpo.2023.104058","volume":"8","author":"A Adams","year":"2023","unstructured":"Adams A, Blawatt S, MacDonald S, Finnick R, Lajeunesse J, Harrison S, et al. Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: a qualitative systematic review. Int J Drug Policy. 2023;8:104058.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1008_CR97","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/08897077.2022.2060438","volume":"43","author":"LW Suen","year":"2022","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. \u201cThe idea is to help people achieve greater success and liberty\u201d: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abuse. 2022;43(1):1147\u201354.","journal-title":"Subst Abuse"},{"key":"1008_CR98","doi-asserted-by":"publisher","first-page":"108550","DOI":"10.1016\/j.jsat.2021.108550","volume":"133","author":"BF Henry","year":"2022","unstructured":"Henry BF, Campbell A, Hunt T, Johnson JK, Mandavia AD, Chaple M, et al. COVID-19 related substance use services policy changes: policymaker perspectives on policy development & implementation. J Subst Abuse Treat. 2022;133:108550.","journal-title":"J Subst Abuse Treat"},{"issue":"228","key":"1008_CR99","doi-asserted-by":"publisher","first-page":"109049","DOI":"10.1016\/j.drugalcdep.2021.109049","volume":"1","author":"LA Goldsamt","year":"2021","unstructured":"Goldsamt LA, Rosenblum A, Appel P, Paris P, Nazia N. The impact of COVID-19 on opioid treatment programs in the United States. Drug Alcohol Depend. 2021;1(228):109049.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1008_CR100","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13722-021-00234-w","volume":"16","author":"L Mackay","year":"2021","unstructured":"Mackay L, Kerr T, Fairbairn N, Grant C, Milloy MJ, Hayashi K. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting. Addict Sci Clin Pract. 2021;16(1):26.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1008_CR101","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-022-00653-1","volume":"19","author":"FN Conway","year":"2022","unstructured":"Conway FN, Samora J, Brinkley K, Jeong H, Clinton N, Claborn KR. Impact of COVID-19 among people who use drugs: a qualitative study with harm reduction workers and people who use drugs. Harm Reduct J. 2022;19(1):72.","journal-title":"Harm Reduct J"},{"key":"1008_CR102","doi-asserted-by":"publisher","first-page":"102904","DOI":"10.1016\/j.drugpo.2020.102904","volume":"93","author":"JJ Palamar","year":"2021","unstructured":"Palamar JJ, Acosta P. Virtual raves and happy hours during COVID-19: new drug use contexts for electronic dance music partygoers. Int J Drug Policy. 2021;93:102904.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1008_CR103","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/add.15620","volume":"117","author":"O Price","year":"2022","unstructured":"Price O, Man N, Bruno R, Dietze P, Salom C, Lenton S, et al. Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the ecstasy and related drugs reporting system, 2016\u201320. Addiction. 2022;117(1):182\u201394.","journal-title":"Addiction"},{"issue":"6","key":"1008_CR104","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/15563650.2019.1657583","volume":"58","author":"H Bach","year":"2020","unstructured":"Bach H, Jenkins V, Aledhaim A, Moayedi S, Schenkel SM, Kim HK. Prevalence of fentanyl exposure and knowledge regarding the risk of its use among emergency department patients with active opioid use history at an urban medical center in Baltimore, Maryland. Clin Toxicol (Phila). 2020;58(6):460\u20135.","journal-title":"Clin Toxicol (Phila)"},{"issue":"74","key":"1008_CR105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drugpo.2019.08.006","volume":"1","author":"M Buresh","year":"2019","unstructured":"Buresh M, Genberg BL, Astemborski J, Kirk GD, Mehta SH. Recent fentanyl use among people who inject drugs: results from a rapid assessment in Baltimore, Maryland. Int J Drug Policy. 2019;1(74):41\u20136.","journal-title":"Int J Drug Policy"},{"issue":"23","key":"1008_CR106","doi-asserted-by":"publisher","first-page":"724","DOI":"10.15585\/mmwr.mm6923a3","volume":"69","author":"Z Dezman","year":"2020","unstructured":"Dezman Z, Schwartz B, Billing A, Massey E, Artigiani EE, Factor J, et al. Notes from the field: high prevalence of fentanyl detected by the maryland emergency department drug surveillance system\u2014Baltimore, Maryland, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(23):724\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"1008_CR107","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10826084.2018.1555597","volume":"54","author":"CA Latkin","year":"2019","unstructured":"Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE. Fentanyl and drug overdose: perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst Use Misuse. 2019;54(6):998\u20131006.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"1008_CR108","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","volume":"50","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore. MD J Psychoact Drugs. 2018;50(2):167\u201376.","journal-title":"MD J Psychoact Drugs"},{"issue":"107","key":"1008_CR109","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.drugpo.2022.103773","volume":"1","author":"A Pilarinos","year":"2022","unstructured":"Pilarinos A, Kwa Y, Joe R, Thulien M, Buxton JA, DeBeck K, et al. Navigating opioid agonist therapy among young people who use illicit opioids in Vancouver, Canada. Int J Drug Policy. 2022;1(107):103773.","journal-title":"Int J Drug Policy"},{"issue":"141","key":"1008_CR110","doi-asserted-by":"publisher","first-page":"108832","DOI":"10.1016\/j.jsat.2022.108832","volume":"1","author":"M Buresh","year":"2022","unstructured":"Buresh M, Nahvi S, Steiger S, Weinstein ZM. Adapting methadone inductions to the fentanyl era. J Subst Abuse Treat. 2022;1(141):108832.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1008_CR111","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/00952990903544802","volume":"36","author":"J Risser","year":"2010","unstructured":"Risser J, Cates A, Rehman H, Risser W. Gender differences in social support and depression among injection drug users in Houston, Texas. Am J Drug Alcohol Abuse. 2010;36(1):18\u201324.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"1008_CR112","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12954-017-0159-9","volume":"14","author":"J Boyd","year":"2017","unstructured":"Boyd J, Fast D, Hobbins M, McNeil R, Small W. Social-structural factors influencing periods of injection cessation among marginalized youth who inject drugs in Vancouver, Canada: an ethno-epidemiological study. Harm Reduct J. 2017;14(1):31.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1008_CR113","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jsat.2012.12.009","volume":"45","author":"SP Hiller","year":"2013","unstructured":"Hiller SP, Syvertsen JL, Lozada R, Ojeda VD. Social support and recovery among Mexican female sex workers who inject drugs. J Subst Abuse Treat. 2013;45(1):44\u201354.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1008_CR114","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.drugalcdep.2013.04.007","volume":"132","author":"R Pabayo","year":"2013","unstructured":"Pabayo R, Alcantara C, Kawachi I, Wood E, Kerr T. The role of depression and social support in non-fatal drug overdose among a cohort of injection drug users in a Canadian setting. Drug Alcohol Depend. 2013;132(3):603\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1008_CR115","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/dar.13456","volume":"41","author":"H Efunnuga","year":"2022","unstructured":"Efunnuga H, Higgs P, Walker S, O\u2019Keefe D. Health service utilisation and access for people who inject drugs during COVID-19. Drug Alcohol Rev. 2022;41(6):1304\u201310.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"1008_CR116","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13011-019-0205-6","volume":"14","author":"R Jalali","year":"2019","unstructured":"Jalali R, Moradi A, Dehghan F, Merzai S, Alikhani M. The exploration of factors related to treatment retention in Narcotics Anonymous members: a qualitative study. Subst Abuse Treat Prevent Policy. 2019;14(1):14.","journal-title":"Subst Abuse Treat Prevent Policy"},{"issue":"1","key":"1008_CR117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0740-5472(02)00243-X","volume":"23","author":"JW Toumbourou","year":"2002","unstructured":"Toumbourou JW, Hamilton M, U\u2019Ren A, Stevens-Jones P, Storey G. Narcotics anonymous participation and changes in substance use and social support. J Subst Abuse Treat. 2002;23(1):61\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"1008_CR118","doi-asserted-by":"publisher","first-page":"108649","DOI":"10.1016\/j.jsat.2021.108649","volume":"131","author":"MS Anvari","year":"2021","unstructured":"Anvari MS, Seitz-Brown CJ, Spencer J, Mulheron M, Abdelwahab S, Borba CPC, et al. \u201cHow can I hug someone now [over the phone]?\u201d: Impacts of COVID-19 on peer recovery specialists and clients in substance use treatment. J Subst Abuse Treat. 2021;131:108649.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"1008_CR119","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/10826084.2021.1901935","volume":"56","author":"F Rahman","year":"2021","unstructured":"Rahman F, Evans N, Bernhardt J. Access to OUD treatment and maintenance of sobriety amid the COVID-19 pandemic. Subst Use Misuse. 2021;56(7):1005\u20139.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"1008_CR120","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/10570314.2020.1786598","volume":"85","author":"AK Barrett","year":"2021","unstructured":"Barrett AK, Murphy MM. Feeling supported in addiction recovery: comparing face-to-face and videoconferencing 12-step meetings. West J Commun. 2021;85(1):123\u201346.","journal-title":"West J Commun"},{"issue":"1","key":"1008_CR121","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/alcalc\/agv071","volume":"51","author":"JF Kelly","year":"2016","unstructured":"Kelly JF, Greene MC, Bergman B, Hoeppner BB, Slaymaker V. The sponsor alliance inventory: assessing the therapeutic bond between 12-step attendees and their sponsors. Alcohol Alcohol. 2016;51(1):32\u20139.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"1008_CR122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13011-018-0167-0","volume":"13","author":"M Stokes","year":"2018","unstructured":"Stokes M, Schultz P, Alpaslan A. Narrating the journey of sustained recovery from substance use disorder. Subst Abuse Treat Prevent Policy. 2018;13(1):35.","journal-title":"Subst Abuse Treat Prevent Policy"},{"issue":"198","key":"1008_CR123","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"1","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;1(198):80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1008_CR124","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/15332560802157065","volume":"8","author":"KO Conner","year":"2008","unstructured":"Conner KO, Rosen D. \u201cYou\u2019re nothing but a junkie\u201d: multiple experiences of stigma in an aging methadone maintenance population. J Soc Work Pract Addict. 2008;8(2):244\u201364.","journal-title":"J Soc Work Pract Addict"},{"issue":"1","key":"1008_CR125","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):88.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1008_CR126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1008_CR127","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12913-022-07832-7","volume":"22","author":"S Bandara","year":"2022","unstructured":"Bandara S, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, et al. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. BMC Health Serv Res. 2022;22(1):418.","journal-title":"BMC Health Serv Res"},{"key":"1008_CR128","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.1016\/j.jsat.2021.108514","volume":"132","author":"PC Treitler","year":"2022","unstructured":"Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Subst Abuse Treat. 2022;132:108514.","journal-title":"J Subst Abuse Treat"},{"issue":"112","key":"1008_CR129","doi-asserted-by":"publisher","first-page":"103931","DOI":"10.1016\/j.drugpo.2022.103931","volume":"1","author":"T Bommersbach","year":"2023","unstructured":"Bommersbach T, Justen M, Bunting AM, Funaro MC, Winstanley EL, Joudrey PJ. Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: a scoping review. Int J Drug Policy. 2023;1(112):103931.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01008-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T06:04:22Z","timestamp":1715148262000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01008-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01008-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board. All participants provided oral informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}